HHS Stock Alert: Halper Sadeh LLC is Investigating Whether Harte Hanks, Inc. is Obtaining a Fair Price for its Shareholders

Halper Sadeh LLC is investigating the proposed sale of Harte Hanks to Star Equity Holdings. Harte Hanks shareholders may elect to receive either $5.00 in cash per share or 0.50 shares of Star Equity’s publicly traded 10% Series A Cumulative Perpetual Preferred Stock for each Harte Hanks share.

Analysis

The key valuation question is the election’s relative value, not the law firm’s investigation: 0.50 preferred shares equal the $5 cash alternative only if the preferred trades at $10 per share. That is a break-even reference, not evidence that either choice is fairly valued; verify the preferred’s current price, trading liquidity, dividend terms, and any election caps or proration in the merger documents. The perpetual preferred substitutes issuer credit, market-liquidity, and duration risk for cash certainty. For Star Equity Holdings (STRR), issuing preferred rather than paying cash may conserve near-term cash but adds a cumulative claim ahead of common equity; the actual burden depends on the security’s governing terms and the size of the election. For Harte Hanks (HHS), the deal spread is exposed to closing conditions, financing and election mechanics, and possible delay. The investor-rights investigation is a process headline, not evidence of misconduct or a likely deal block; any settlement or delay risk is unquantified. In days, watch HHS’s price versus the cash value and the preferred’s executable bid. Over 1–3 months, filings, shareholder vote, and closing updates are the catalysts. Over 6–18 months, STRR’s ability to service cumulative preferred distributions and the preferred’s liquidity matter more than the headline coupon. No trade is justified from the supplied information alone.

Key Decisions for Investors

• Do not treat the investigation announcement as a standalone bearish catalyst. Reassess only if it produces a court action, material disclosure, negotiated change, or measurable closing delay.
• For HHS, monitor the offer spread against $5 and confirm closing conditions, election limits, and expected timing before considering merger-arbitrage exposure. A widening spread without a change in deal terms is an alert to recheck completion risk, not an automatic entry.
• For the preferred-stock election, compare its live, executable price with the $10-per-share break-even and review dividend base, redemption provisions, ranking, and trading volume. Without those details, avoid substituting it for cash on headline yield alone.
• For STRR, verify the amount of preferred stock likely to be issued and its distribution terms in the transaction filings; a larger-than-expected issuance or adverse funding terms would be the clearest potential negative catalyst. Falsify this concern if filings show limited issuance and the company demonstrates capacity to meet the obligations.